Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

CATALYST BANCORP, INC. (CLST)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 1
  • 1 comments

Catalyst Bancorp, Inc. Announces 2026 Second Quarter Results

Market reaction Comment Full text

CANADIAN SOLAR INC. (CSIQ)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

Canadian Solars U.S.-Manufactured TOPCon and HJT HP Modules Achieve FM Approvals Recognition for Their Severe Hail Resilience

Market reaction Comment Full text

HAMILTON LANE INC (HLNE)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

Hamilton Lane Serves as Sole Lead Investor in Cynosure Partners Single-Asset Continuation Vehicle

Market reaction Comment Full text

BUILDERS FIRSTSOURCE, INC. (BLDR)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

Builders FirstSource Reports Second Quarter 2026 Results

Market reaction Comment Full text

VIRTUS INVESTMENT PARTNERS, INC. (VRTS)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

Virtus Investment Partners Announces Financial Results for Second Quarter 2026

Market reaction Comment Full text

DAQO NEW ENERGY CORP. (DQ)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

Daqo New Energy Issues Its 2025 Environmental, Social and Governance (ESG) Report

Market reaction Comment Full text

HERSHEY CO (HSY)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 1
  • 1 comments

Hershey Declares Quarterly Dividends

Market reaction Comment Full text

OIL STATES INTERNATIONAL, INC (OIS)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 1
  • 1 comments

Oil States Announces Second Quarter 2026 Results

Market reaction Comment Full text

AMC NETWORKS INC. (AMCX)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 1
  • 1 comments

AMC Global Media Inc. Reports Second Quarter 2026 Results

Market reaction Comment Full text

EYEPOINT, INC. (EYPT)

  • Business News
  • July 30, 2026, 11:00 UTC
  • 0
  • 1 comments

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

Market reaction Comment Full text
  • Previous
  • 40
  • 41
  • 42
  • 43
  • 44
  • Next

Search

News categories

  • Technical Exchange News(14009)
  • Event(6229)
  • SEC News(355384)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(215696)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin